InsiderSource
BCAX

Bicara Therapeutics Inc.

SEC CIK 2023658
$26.87 +85.4% · 90 days
90-day buys
$0
0 open-market
90-day sells
$1.72M
10 open-market
Net insider flow
−$1.72M
Net selling
Filings shown
85
Most recent
Net income (FY2025)
−$137.95M
Reported
Total assets
$430.99M
Balance sheet
Source
SEC XBRL
From 10-K/10-Q
Advertisement

At a glance

Over the last 90 days, insiders at BCAX have sold a net $1.72M of stock (0 open-market buys vs 10 sells).

Largest recent trade: Ra Capital Management, L.p., BCAX's 10% owner, spent $4.8M of their own money on 300,000 shares at $16, growing their stake 7%. Their tracked buys have a 79% win rate.

Most active filer: Mazumdar Claire, with 26 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for BCAX, newest first
View on SEC EDGAR ↗
BCAX
Bicara Therapeutics Inc.
Sell Hyep Ivan · Chief Financial Officer · Open-market sale · filed May 26, 2026 ΔOwn −6.0%

Hyep Ivan sold $187.9K of BCAX, trimming their stake 6%.

−$187.9K
9,200 sh @ $20
BCAX
Bicara Therapeutics Inc.
Sell Mazumdar Claire · Director, Chief Executive Officer · Open-market sale · filed May 20, 2026 ΔOwn −3.2%

Mazumdar Claire sold $240K of BCAX, trimming their stake 3%.

−$240K
12,022 sh @ $20
BCAX
Bicara Therapeutics Inc.
Sell Mazumdar Claire · Director, Chief Executive Officer · Open-market sale · filed May 20, 2026 ΔOwn −0.8%

Mazumdar Claire sold $60.6K of BCAX, trimming their stake 1%.

−$60.6K
2,978 sh @ $20
Advertisement
BCAX
Bicara Therapeutics Inc.
Sell Cohlhepp Ryan · Director, President and COO · Open-market sale · filed May 18, 2026 ΔOwn −3.9%

Cohlhepp Ryan sold $162.3K of BCAX, trimming their stake 4%.

−$162.3K
8,000 sh @ $20
BCAX
Bicara Therapeutics Inc.
Sell Cohlhepp Ryan · Director, President and COO · Open-market sale · filed May 18, 2026 ΔOwn −2.3%

Cohlhepp Ryan sold $91.3K of BCAX, trimming their stake 2%.

−$91.3K
4,500 sh @ $20
BCAX
Bicara Therapeutics Inc.
Sell Raben David · Chief Medical Officer · Open-market sale · filed Apr 28, 2026 ΔOwn −9.0%

Raben David sold $125.8K of BCAX, trimming their stake 9%.

−$125.8K
5,500 sh @ $23
BCAX
Bicara Therapeutics Inc.
Sell Hyep Ivan · Chief Financial Officer · Open-market sale · filed Apr 22, 2026 ΔOwn −6.0%

Hyep Ivan sold $211.6K of BCAX, trimming their stake 6%.

−$211.6K
9,200 sh @ $23
BCAX
Bicara Therapeutics Inc.
Sell Mazumdar Claire · Director, Chief Executive Officer · Open-market sale · filed Apr 20, 2026 ΔOwn −4.0%

Mazumdar Claire sold $354.1K of BCAX, trimming their stake 4%.

−$354.1K
15,000 sh @ $24
BCAX
Bicara Therapeutics Inc.
Sell Cohlhepp Ryan · Director, President and COO · Open-market sale · filed Apr 17, 2026 ΔOwn −3.8%

Cohlhepp Ryan sold $184.1K of BCAX, trimming their stake 4%.

−$184.1K
8,000 sh @ $23
BCAX
Bicara Therapeutics Inc.
Sell Cohlhepp Ryan · Director, President and COO · Open-market sale · filed Apr 17, 2026 ΔOwn −2.2%

Cohlhepp Ryan sold $103.5K of BCAX, trimming their stake 2%.

−$103.5K
4,500 sh @ $23
BCAX
Bicara Therapeutics Inc.
Sell Raben David · Chief Medical Officer · Open-market sale · filed Mar 26, 2026 ΔOwn −9.0%

Raben David sold $104.2K of BCAX, trimming their stake 9%.

−$104.2K
5,500 sh @ $19
BCAX
Bicara Therapeutics Inc.
Sell Hyep Ivan · Chief Financial Officer · Open-market sale · filed Mar 24, 2026 ΔOwn −6.0%

Hyep Ivan sold $170.3K of BCAX, trimming their stake 6%.

−$170.3K
9,200 sh @ $19
BCAX
Bicara Therapeutics Inc.
Sell Mazumdar Claire · Director, Chief Executive Officer · Open-market sale · filed Mar 20, 2026 ΔOwn −0.5%

Mazumdar Claire sold $30.2K of BCAX.

−$30.2K
1,596 sh @ $19
BCAX
Bicara Therapeutics Inc.
Sell Mazumdar Claire · Director, Chief Executive Officer · Open-market sale · filed Mar 20, 2026 ΔOwn −2.0%

Mazumdar Claire sold $129.7K of BCAX, trimming their stake 2%.

−$129.7K
6,905 sh @ $19
BCAX
Bicara Therapeutics Inc.
Sell Mazumdar Claire · Director, Chief Executive Officer · Open-market sale · filed Mar 20, 2026 ΔOwn −1.9%

Mazumdar Claire sold $122.4K of BCAX, trimming their stake 2%.

−$122.4K
6,499 sh @ $19
Advertisement

About BCAX insider activity

This page tracks every recent Form 4 filed for Bicara Therapeutics Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is BCAX insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Bicara Therapeutics Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.